# Breakthroughs in Alzheimer’s Treatment This Week! Newsy: Alzheimer’s News Weekly Published: 2025-12-01T14:30:00.664Z Source: https://newsyai.com/edition/a783b554-b2a8-4bbc-82e1-f5cf3b941e26 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # The Alzheimer’s Treatment Briefing Coverage period: November 25–December 1, 2025 (U.S.) Below are the most important, genuinely new developments from the past seven days that affect how we treat — or soon might treat — Alzheimer’s disease. ## Top stories (ranked) 1) Merck’s anti‑tau program gets an FDA Fast Track and shows first‑in‑human data at CTAD - Overview - This morning (Dec 1), Merck said its antibody MK‑2214, which targets a disease‑related form of tau, received FDA Fast Track status. Merck is also presenting first‑in‑human results for MK‑2214 and early data on MK‑1167 (an α7 nicotinic receptor modulator) at the CTAD 2025 meeting in San Diego this week. Fast Track can speed reviews and let companies submit data on a rolling basis. ([merck.com](https://www.merck.com/news/merck-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/?utm_source=openai)) - Why this matters - Today’s approved drugs remove amyloid. A safe, effective tau‑targeting therapy would attack the other key protein that drives worsening symptoms, and could be used alongside amyloid‑removing drugs to strengthen and prolong benefit. FDA Fast Track signals urgency and may shorten timelines to larger trials and potential approval. ([merck.com](https://www.merck.com/news/merck-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/?utm_source=openai)) 2) New clinic data: higher blood p‑tau at baseline flags both faster decline and higher ARIA risk on lecanemab - Overview - A real‑world study (published Nov 24) found that people starting lecanemab with higher levels of phosphorylated tau in blood were more likely to decline faster and to develop ARIA (the brain swelling or tiny bleeds that require MRI checks) during treatment. The work used routine clinical practice data rather than a controlled trial. ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01912-6?utm_source=openai)) - Why this matters - A simple blood measure could help clinics personalize care: who may need closer MRI monitoring, who might be at higher risk for side effects, and how to set expectations about benefit. That can make treatment safer and more efficient without adding new scans. ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01912-6?utm_source=openai)) 3) After semaglutide’s Phase 3 miss, researchers pivot GLP‑1 drugs toward prevention rather than treatment - Overview - Following Novo Nordisk’s Nov 24 announcement that oral semaglutide failed to slow decline in two large trials of early Alzheimer’s, researchers highlighted plans to test GLP‑1 medicines earlier — in people at risk but not yet symptomatic — given metabolic risk links and some encouraging biomarker signals. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/?utm_source=openai)) - Why this matters - For people with symptoms today, GLP‑1s shouldn’t be expected to help cognition. But prevention studies — starting years earlier — may still be worthwhile. Expect funding and trial designs to shift in that direction while symptomatic care stays focused on anti‑amyloid and emerging anti‑tau therapies. ([reuters.com](https://www.reuters.com/sustainability/boards-policy-regulation/undeterred-by-novo-nordisk-failure-scientists-consider-glp-1s-alzheimers-2025-11-25/?utm_source=openai)) 4) Oral candidate ALZ‑801 (valiltramiprosate) teed up to share multi‑study results this week — with a focus on APOE4/4 - Overview - Alzheon announced it will present nine posters at CTAD (Dec 1–4), including Phase 3 topline data in APOE4/4 patients, long‑term extension outcomes, and modeling that links effects to preserved brain volume — emphasizing an oral, upstream approach that aims to block toxic amyloid oligomers. These are company‑sponsored analyses that will get scientific scrutiny onsite. ([businesswire.com](https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025?utm_source=openai)) - Why this matters - If results hold up, an oral option with a clean safety profile — particularly for the high‑risk APOE4/4 group — could broaden how we treat or sequence therapies. It’s not a replacement for today’s antibodies yet, but it could become a practical alternative or partner. ([businesswire.com](https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025?utm_source=openai)) 5) Practical note for programs: CTAD opens with multiple sessions on starting lecanemab by injection and scaling real‑world use - Overview - CTAD’s agenda includes new data on beginning lecanemab with injections (instead of IV) and updates from the ALZ‑NET registry on real‑world safety and workflows. The meeting runs Dec 1–4 in San Diego; watch for posters and talks over the next 72 hours. ([media-us.eisai.com](https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment%2C-Subcutaneous-Initiation-Dosing%2C-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference?utm_source=openai)) - Why this matters - If “start‑by‑injection” proves safe and workable, it could reduce infusion‑center bottlenecks and speed access — important as blood tests expand detection and as FDA now recommends earlier MRI monitoring (between infusions 2 and 3) to catch ARIA sooner. Clinics can plan staffing and protocols accordingly. ([media-us.eisai.com](https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment%2C-Subcutaneous-Initiation-Dosing%2C-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference?utm_source=openai)) ## What this means for care right now - Anti‑amyloid antibodies remain the only proven disease‑slowing option for symptomatic early Alzheimer’s; tailor MRI schedules with the FDA’s added early scan and consider baseline blood p‑tau to triage monitoring intensity. ([fda.gov](https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab?utm_source=openai)) - Tau is the next major front: Merck’s Fast Track and multiple tau programs at CTAD point to combination strategies (amyloid + tau) as a near‑term research focus. ([merck.com](https://www.merck.com/news/merck-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/?utm_source=openai)) - GLP‑1 drugs are unlikely to help once symptoms are present; any role is likelier in prevention studies. Manage expectations accordingly. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/?utm_source=openai)) ## What to watch in the next 3–5 days (CTAD) - Lecanemab: data on starting with injections and real‑world outcomes (ALZ‑NET). ([media-us.eisai.com](https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment%2C-Subcutaneous-Initiation-Dosing%2C-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference?utm_source=openai)) - Tau agents: first‑in‑human MK‑2214 and other tau‑targeting updates that could foreshadow combo therapy design. ([merck.com](https://www.merck.com/news/merck-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/?utm_source=openai)) - Oral options: additional ALZ‑801 analyses in APOE4/4 and longer‑term safety. ([businesswire.com](https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025?utm_source=openai)) References (key sources) - Merck CTAD/Fast Track announcement for MK‑2214 and MK‑1167 (Dec 1, 2025). ([merck.com](https://www.merck.com/news/merck-showcases-data-for-alzheimers-disease-candidates-mk-2214-and-mk-1167-at-ctad-2025/?utm_source=openai)) - Clinic study: baseline blood p‑tau predicts decline and ARIA on lecanemab (Nov 24, 2025). ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01912-6?utm_source=openai)) - Reuters coverage of semaglutide trial failure (Nov 24, 2025) and the prevention pivot (Nov 25, 2025). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/?utm_source=openai)) - CTAD 2025 program details and timing (Dec 1–4, 2025). ([ctad-alzheimer.com](https://www.ctad-alzheimer.com/ctad-2025?utm_source=openai)) - Eisai preview of lecanemab injection initiation and real‑world presentations at CTAD. ([media-us.eisai.com](https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment%2C-Subcutaneous-Initiation-Dosing%2C-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference?utm_source=openai)) - FDA safety communication recommending an extra early MRI for people on lecanemab (Aug 28, 2025). ([fda.gov](https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab?utm_source=openai)) - Alzheon CTAD presentation plans for ALZ‑801 (Nov 25, 2025 Business Wire; Nov 19, 2025 company page). ([businesswire.com](https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025?utm_source=openai)) If you’d like, I can push a same‑day CTAD micro‑update as key treatment findings drop (Dec 1–4).